- Home
- INCY vs YMM Comparison
INCY vs YMM Comparison
Compare INCY & YMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- YMM
- Stock Information
- Founded
- INCY 1991
- YMM 2011
- Country
- INCY United States
- YMM China
- Employees
- INCY N/A
- YMM N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- YMM Computer Software: Prepackaged Software
- Sector
- INCY Health Care
- YMM Technology
- Exchange
- INCY Nasdaq
- YMM Nasdaq
- Market Cap
- INCY 17.0B
- YMM 12.3B
- IPO Year
- INCY 1993
- YMM 2021
- Fundamental
- Price
- INCY $105.57
- YMM $12.67
- Analyst Decision
- INCY Buy
- YMM Buy
- Analyst Count
- INCY 19
- YMM 3
- Target Price
- INCY $89.19
- YMM $13.00
- AVG Volume (30 Days)
- INCY 2.8M
- YMM 5.7M
- Earning Date
- INCY 10-28-2025
- YMM 11-17-2025
- Dividend Yield
- INCY N/A
- YMM 1.51%
- EPS Growth
- INCY 3878.02
- YMM 64.18
- EPS
- INCY 5.90
- YMM 0.55
- Revenue
- INCY $4,813,105,000.00
- YMM $1,695,281,415.00
- Revenue This Year
- INCY $19.33
- YMM $6.27
- Revenue Next Year
- INCY $10.47
- YMM $6.98
- P/E Ratio
- INCY $17.95
- YMM $22.48
- Revenue Growth
- INCY 18.09
- YMM 25.14
- 52 Week Low
- INCY $53.56
- YMM $8.20
- 52 Week High
- INCY $108.81
- YMM $14.07
- Technical
- Relative Strength Index (RSI)
- INCY 80.92
- YMM 49.31
- Support Level
- INCY $91.16
- YMM $12.13
- Resistance Level
- INCY $106.47
- YMM $12.88
- Average True Range (ATR)
- INCY 4.31
- YMM 0.35
- MACD
- INCY 1.48
- YMM -0.03
- Stochastic Oscillator
- INCY 88.14
- YMM 45.67
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.